J Leukoc Biol. 2026 May 23:qiag065. doi: 10.1093/jleuko/qiag065. Online ahead of print.
ABSTRACT
Sarcoidosis (SRS) is a multi-organ granulomatous disorder that predominantly affects the eyes, lungs, and skin. Biopsy, the standard for a definitive SRS diagnosis, is often impractical for ocular sarcoidosis (OSRS) due to the delicate nature of the eye and risks associated with surgical procedures such as inflammation, infection, retinal detachment, and cataracts. OSRS is typically treated with steroids and immunosuppressive medications. However, because infectious uveitis exhibits a similar clinical presentation as OSRS, there is an incipient risk of inappropriate treatment without a definitive diagnosis. Failing to prescribe immunosuppressive medications to OSRS patients can lead to scarring and permanent blindness; conversely, prescribing this treatment to infectious uveitis patients risks exacerbating the infection and associated pathologies. Saliva is an emerging diagnostic biofluid which is easy to collect, cost-effective, and is well-tolerated by patients. Although saliva has been used to identify biomarkers for diseases like cancer and diabetes, its use in diagnosing ocular diseases remains limited. This review provides an overview of SRS and OSRS, the utility of saliva as a diagnostic, and a pilot experiment to test if saliva could be used for OSRS diagnosis.
PMID:42178503 | DOI:10.1093/jleuko/qiag065